Screener
BridgeBio Pharma BBIO Cumulative Cost Basis
Cumulative Cost Basis at other companies
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis.
The source filing: BridgeBio Pharma’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:31 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001743881-26-000019
| Line item | Amortized Cost Basis | Unrealized Gains | Unrealized Losses | Estimated Fair Value |
|---|---|---|---|---|
| U.S. Treasury securities | 174,121 | 2 | (1) | 174,122 |
| Agency discount notes | 16,349 | — | — | 16,349 |
| Total cash equivalents | $550,707 | $2 | $(1) | $550,708 |
| Marketable securities: | ||||
| U.S. Treasury securities | 43,785 | — | (8) | 43,777 |
| Agency discount notes | 16,519 | — | (1) | 16,518 |
| Total marketable securities | 60,304 | — | (9) | 60,295 |
| Total cash equivalents and marketable securities | $611,011 | $2 | $(10) | $611,003 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is BridgeBio Pharma's cumulative cost basis?
- BridgeBio Pharma (BBIO) reported cumulative cost basis of $60.3M in Q1 2026.
Ask your AI about BridgeBio Pharma's cumulative cost basis.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude